Bisphosphonate use in chronic kidney disease: Association with adynamic bone disease in a bone histology series

Richard Amerling, Nikolas B. Harbord, James M. Pullman, Donald A. Feinfeld

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Dual X-ray absorptiometry is the standard diagnostic modality for identification of low bone mineral density, a finding which is in the general population usually indicative of osteopenia or osteoporosis. However, chronic kidney disease (CKD) patients diagnosed with osteopenia or osteoporosis may in actual fact have renal osteodystrophy with high or low bone turnover. While bisphosphonates are currently prescribed for the prevention of fractures in osteoporosis and high-risk osteopenic patients, the clinical utility of bisphosphonate therapy in CKD has not been established. Furthermore, bisphosphonates accumulate in bone, inhibit osteoclasts, and may cause or exacerbate low-turnover (adynamic) bone disease - particularly in patients presenting with low parathyroid hormone (PTH) levels or receiving treatment for secondary hyperparathyroidism. Bone biopsy with non-decalcified histopathology remains the gold standard for the identification and evaluation of bone disorders, including osteoporosis and renal osteodystrophy. Thirteen CKD patients (stage II-IV), referred to our clinic over a 12-month period, were identified as having taken bisphosphonates from 4 to >60 months after a diagnosis of osteopenia or osteoporosis. All patients underwent biopsies of trabecular bone from the iliac crest following oral administration of time-separated doses of doxycycline and tetracycline. Bone pathology was assessed after processing for mineralized histology. For all patients, clinical data collection includMagnesium in Chronic Kidney Disease: Challenges Magnesium in Chronic Kidney Disease: Challengesed assessment of likely causes of kidney disease, MDRD glomerular filtration rate, calcium-phosphate product, intact PTH level, alkaline phosphatase, and bisphosphonate exposure. All 13 patients were diagnosed with adynamic bone on biopsy evaluation. Eleven biopsies revealed decreased cancellous bone mass; 8 showed decreased osteoid surface; 8 disclosed decreased osteoid thickness, and all 13 demonstrated low or low-normal osteoclast/osteoblast interface. Assessment of dynamic bone formation demonstrated decreased or absent single- or double-labeled osteoid in all 13 bone specimens. Based on these observations, the use of bisphosphonates in CKD cannot be recommended.

Original languageEnglish (US)
Pages (from-to)293-299
Number of pages7
JournalBlood Purification
Volume29
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Bone Diseases
Diphosphonates
Chronic Renal Insufficiency
Histology
Osteoporosis
Bone and Bones
Metabolic Bone Diseases
Chronic Kidney Disease-Mineral and Bone Disorder
Biopsy
Osteoclasts
Parathyroid Hormone
Secondary Hyperparathyroidism
Bone Remodeling
Doxycycline
Photon Absorptiometry
Kidney Diseases
Tetracycline
Osteoblasts
Glomerular Filtration Rate
Osteogenesis

Keywords

  • Alendronate
  • Bisphosphonates
  • Chronic kidney disease
  • Osteoid
  • Osteopenia
  • Osteoporosis
  • Renal diseases

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Cite this

Bisphosphonate use in chronic kidney disease : Association with adynamic bone disease in a bone histology series. / Amerling, Richard; Harbord, Nikolas B.; Pullman, James M.; Feinfeld, Donald A.

In: Blood Purification, Vol. 29, No. 3, 03.2010, p. 293-299.

Research output: Contribution to journalArticle

Amerling, Richard ; Harbord, Nikolas B. ; Pullman, James M. ; Feinfeld, Donald A. / Bisphosphonate use in chronic kidney disease : Association with adynamic bone disease in a bone histology series. In: Blood Purification. 2010 ; Vol. 29, No. 3. pp. 293-299.
@article{80964be371ab4710a456a9bf70dcc781,
title = "Bisphosphonate use in chronic kidney disease: Association with adynamic bone disease in a bone histology series",
abstract = "Dual X-ray absorptiometry is the standard diagnostic modality for identification of low bone mineral density, a finding which is in the general population usually indicative of osteopenia or osteoporosis. However, chronic kidney disease (CKD) patients diagnosed with osteopenia or osteoporosis may in actual fact have renal osteodystrophy with high or low bone turnover. While bisphosphonates are currently prescribed for the prevention of fractures in osteoporosis and high-risk osteopenic patients, the clinical utility of bisphosphonate therapy in CKD has not been established. Furthermore, bisphosphonates accumulate in bone, inhibit osteoclasts, and may cause or exacerbate low-turnover (adynamic) bone disease - particularly in patients presenting with low parathyroid hormone (PTH) levels or receiving treatment for secondary hyperparathyroidism. Bone biopsy with non-decalcified histopathology remains the gold standard for the identification and evaluation of bone disorders, including osteoporosis and renal osteodystrophy. Thirteen CKD patients (stage II-IV), referred to our clinic over a 12-month period, were identified as having taken bisphosphonates from 4 to >60 months after a diagnosis of osteopenia or osteoporosis. All patients underwent biopsies of trabecular bone from the iliac crest following oral administration of time-separated doses of doxycycline and tetracycline. Bone pathology was assessed after processing for mineralized histology. For all patients, clinical data collection includMagnesium in Chronic Kidney Disease: Challenges Magnesium in Chronic Kidney Disease: Challengesed assessment of likely causes of kidney disease, MDRD glomerular filtration rate, calcium-phosphate product, intact PTH level, alkaline phosphatase, and bisphosphonate exposure. All 13 patients were diagnosed with adynamic bone on biopsy evaluation. Eleven biopsies revealed decreased cancellous bone mass; 8 showed decreased osteoid surface; 8 disclosed decreased osteoid thickness, and all 13 demonstrated low or low-normal osteoclast/osteoblast interface. Assessment of dynamic bone formation demonstrated decreased or absent single- or double-labeled osteoid in all 13 bone specimens. Based on these observations, the use of bisphosphonates in CKD cannot be recommended.",
keywords = "Alendronate, Bisphosphonates, Chronic kidney disease, Osteoid, Osteopenia, Osteoporosis, Renal diseases",
author = "Richard Amerling and Harbord, {Nikolas B.} and Pullman, {James M.} and Feinfeld, {Donald A.}",
year = "2010",
month = "3",
doi = "10.1159/000276666",
language = "English (US)",
volume = "29",
pages = "293--299",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Bisphosphonate use in chronic kidney disease

T2 - Association with adynamic bone disease in a bone histology series

AU - Amerling, Richard

AU - Harbord, Nikolas B.

AU - Pullman, James M.

AU - Feinfeld, Donald A.

PY - 2010/3

Y1 - 2010/3

N2 - Dual X-ray absorptiometry is the standard diagnostic modality for identification of low bone mineral density, a finding which is in the general population usually indicative of osteopenia or osteoporosis. However, chronic kidney disease (CKD) patients diagnosed with osteopenia or osteoporosis may in actual fact have renal osteodystrophy with high or low bone turnover. While bisphosphonates are currently prescribed for the prevention of fractures in osteoporosis and high-risk osteopenic patients, the clinical utility of bisphosphonate therapy in CKD has not been established. Furthermore, bisphosphonates accumulate in bone, inhibit osteoclasts, and may cause or exacerbate low-turnover (adynamic) bone disease - particularly in patients presenting with low parathyroid hormone (PTH) levels or receiving treatment for secondary hyperparathyroidism. Bone biopsy with non-decalcified histopathology remains the gold standard for the identification and evaluation of bone disorders, including osteoporosis and renal osteodystrophy. Thirteen CKD patients (stage II-IV), referred to our clinic over a 12-month period, were identified as having taken bisphosphonates from 4 to >60 months after a diagnosis of osteopenia or osteoporosis. All patients underwent biopsies of trabecular bone from the iliac crest following oral administration of time-separated doses of doxycycline and tetracycline. Bone pathology was assessed after processing for mineralized histology. For all patients, clinical data collection includMagnesium in Chronic Kidney Disease: Challenges Magnesium in Chronic Kidney Disease: Challengesed assessment of likely causes of kidney disease, MDRD glomerular filtration rate, calcium-phosphate product, intact PTH level, alkaline phosphatase, and bisphosphonate exposure. All 13 patients were diagnosed with adynamic bone on biopsy evaluation. Eleven biopsies revealed decreased cancellous bone mass; 8 showed decreased osteoid surface; 8 disclosed decreased osteoid thickness, and all 13 demonstrated low or low-normal osteoclast/osteoblast interface. Assessment of dynamic bone formation demonstrated decreased or absent single- or double-labeled osteoid in all 13 bone specimens. Based on these observations, the use of bisphosphonates in CKD cannot be recommended.

AB - Dual X-ray absorptiometry is the standard diagnostic modality for identification of low bone mineral density, a finding which is in the general population usually indicative of osteopenia or osteoporosis. However, chronic kidney disease (CKD) patients diagnosed with osteopenia or osteoporosis may in actual fact have renal osteodystrophy with high or low bone turnover. While bisphosphonates are currently prescribed for the prevention of fractures in osteoporosis and high-risk osteopenic patients, the clinical utility of bisphosphonate therapy in CKD has not been established. Furthermore, bisphosphonates accumulate in bone, inhibit osteoclasts, and may cause or exacerbate low-turnover (adynamic) bone disease - particularly in patients presenting with low parathyroid hormone (PTH) levels or receiving treatment for secondary hyperparathyroidism. Bone biopsy with non-decalcified histopathology remains the gold standard for the identification and evaluation of bone disorders, including osteoporosis and renal osteodystrophy. Thirteen CKD patients (stage II-IV), referred to our clinic over a 12-month period, were identified as having taken bisphosphonates from 4 to >60 months after a diagnosis of osteopenia or osteoporosis. All patients underwent biopsies of trabecular bone from the iliac crest following oral administration of time-separated doses of doxycycline and tetracycline. Bone pathology was assessed after processing for mineralized histology. For all patients, clinical data collection includMagnesium in Chronic Kidney Disease: Challenges Magnesium in Chronic Kidney Disease: Challengesed assessment of likely causes of kidney disease, MDRD glomerular filtration rate, calcium-phosphate product, intact PTH level, alkaline phosphatase, and bisphosphonate exposure. All 13 patients were diagnosed with adynamic bone on biopsy evaluation. Eleven biopsies revealed decreased cancellous bone mass; 8 showed decreased osteoid surface; 8 disclosed decreased osteoid thickness, and all 13 demonstrated low or low-normal osteoclast/osteoblast interface. Assessment of dynamic bone formation demonstrated decreased or absent single- or double-labeled osteoid in all 13 bone specimens. Based on these observations, the use of bisphosphonates in CKD cannot be recommended.

KW - Alendronate

KW - Bisphosphonates

KW - Chronic kidney disease

KW - Osteoid

KW - Osteopenia

KW - Osteoporosis

KW - Renal diseases

UR - http://www.scopus.com/inward/record.url?scp=74249085619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249085619&partnerID=8YFLogxK

U2 - 10.1159/000276666

DO - 10.1159/000276666

M3 - Article

C2 - 20090316

AN - SCOPUS:74249085619

VL - 29

SP - 293

EP - 299

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 3

ER -